中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 2
Feb.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(2): 397-401

Role of NOD-like receptor protein 3 inflammasome in the development and progression of hepatocellular carcinoma

DOI: 10.12449/JCH240229
  • 1a.

    Department of Pediatric Surgery，General Hospital of Ningxia Medical University，Yinchuan 750000，China

  • 1b.

    Department of Hepatobiliary Surgery，General Hospital of Ningxia Medical University，Yinchuan 750000，China

  • 2.

    Ningxia Medical University，Yinchuan 750000，China

Research funding:

Key Project of Ningxia Natural Science Foundation (2023AAC02073);

School Level Project of Ningxia Medical University (XM2023022)

More Information
  • Corresponding author: CHEN Bendong， chenbendong@nxmu.edu.cn （ORCID： 0009-0001-8566-9269）
  • Received Date: 2023-06-02
  • Accepted Date: 2023-08-01
  • Published Date: 2024-02-19
    Abstract
  • In recent years， NOD-like receptor protein 3 （NLRP3） inflammasome in tumors has become a research hotspot， especially in melanoma， colorectal cancer， lung cancer， and breast cancer， and more and more evidence has shown that inflammation plays a role in the development， progression， angiogenesis， and invasion of cancer. Hepatocellular carcinoma （HCC） is the most common type of primary liver cancer， and there are still controversies over the role of NLRP3 inflammasome in the development and progression of HCC. Therefore， this article reviews the potential impact of NLRP3 inflammasome in the progression of HCC and its mechanism of action in anticancer therapy， and it is believed that NLRP3 inflammasome can be used as an effective therapeutic target for HCC patients.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    LI Z, ZHU JY. Interpretation of standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 5): 1027- 1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010.

    李照, 朱继业.《原发性肝癌诊疗指南(2022年版)》解读[J]. 临床肝胆病杂志, 2022, 38( 5): 1027- 1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010.
    [2]
    YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 10): 589- 604. DOI: 10.1038/s41575-019-0186-y.
    [3]
    HUANG XY, CHAO X, HUANG F. Research progress on role of pyroptosis in progress of primary liver cancer[J]. Drug Eval Res, 2021, 44( 7): 1535- 1540. DOI: 10.7501/j.issn.1674-6376.2021.07.026.

    黄鑫悦, 晁旭, 黄峰. 细胞焦亡在原发性肝癌进展中的作用研究进展[J]. 药物评价研究, 2021, 44( 7): 1535- 1540. DOI: 10.7501/j.issn.1674-6376.2021.07.026.
    [4]
    KARKI R, KANNEGANTI TD. Diverging inflammasome signals in tumorigenesis and potential targeting[J]. Nat Rev Cancer, 2019, 19( 4): 197- 214. DOI: 10.1038/s41568-019-0123-y.
    [5]
    KANTONO M, GUO BC. Inflammasomes and cancer: The dynamic role of the inflammasome in tumor development[J]. Front Immunol, 2017, 8: 1132. DOI: 10.3389/fimmu.2017.01132.
    [6]
    XIA XJ, WANG X, CHENG Z, et al. The role of pyroptosis in cancer: Pro-cancer or pro-“host”?[J]. Cell Death Dis, 2019, 10( 9): 650. DOI: 10.1038/s41419-019-1883-8.
    [7]
    DAGENAIS M, SKELDON A, SALEH M. The inflammasome: In memory of Dr. Jurg Tschopp[J]. Cell Death Differ, 2012, 19( 1): 5- 12. DOI: 10.1038/cdd.2011.159.
    [8]
    SCHRODER K, TSCHOPP J. The inflammasomes[J]. Cell, 2010, 140( 6): 821- 832. DOI: 10.1016/j.cell.2010.01.040.
    [9]
    MISSIROLI S, PERRONE M, BONCOMPAGNI C, et al. Targeting the NLRP3 inflammasome as a new therapeutic option for overcoming cancer[J]. Cancers, 2021, 13( 10): 2297. DOI: 10.3390/cancers13102297.
    [10]
    MALIK A, KANNEGANTI TD. Inflammasome activation and assembly at a glance[J]. J Cell Sci, 2017, 130( 23): 3955- 3963. DOI: 10.1242/jcs.207365.
    [11]
    PATEL MN, CARROLL RG, GALVÁN-PEÑA S, et al. Inflammasome priming in sterile inflammatory disease[J]. Trends Mol Med, 2017, 23( 2): 165- 180. DOI: 10.1016/j.molmed.2016.12.007.
    [12]
    MOOSSAVI M, PARSAMANESH N, BAHRAMI A, et al. Role of the NLRP3 inflammasome in cancer[J]. Mol Cancer, 2018, 17( 1): 158. DOI: 10.1186/s12943-018-0900-3.
    [13]
    TSAI YM, CHIANG KH, HUNG JY, et al. Der f1 induces pyroptosis in human bronchial epithelia via the NLRP3 inflammasome[J]. Int J Mol Med, 2018, 41( 2): 757- 764. DOI: 10.3892/ijmm.2017.3310.
    [14]
    TANG YL, TAO Y, ZHU L, et al. Role of NLRP3 inflammasome in hepatocellular carcinoma: A double-edged sword[J]. Int Immunopharmacol, 2023, 118: 110107. DOI: 10.1016/j.intimp.2023.110107.
    [15]
    SHI JJ, ZHAO Y, WANG K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526( 7575): 660- 665. DOI: 10.1038/nature15514.
    [16]
    HAMARSHEH S, ZEISER R. NLRP3 inflammasome activation in cancer: A double-edged sword[J]. Front Immunol, 2020, 11: 1444. DOI: 10.3389/fimmu.2020.01444.
    [17]
    MAMUN A AL, MIMI AA, AZIZ MA, et al. Role of pyroptosis in cancer and its therapeutic regulation[J]. Eur J Pharmacol, 2021, 910: 174444. DOI: 10.1016/j.ejphar.2021.174444.
    [18]
    INCHINGOLO R, POSA A, MARIAPPAN M, et al. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions[J]. World J Gastroenterol, 2019, 25( 32): 4614- 4628. DOI: 10.3748/wjg.v25.i32.4614.
    [19]
    CHEN WQ, ZHENG RS, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66( 2): 115- 132. DOI: 10.3322/caac.21338.
    [20]
    ZENG HM, CHEN WQ, ZHENG RS, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6( 5): e555- e567. DOI: 10.1016/S2214-109X(18)30127-X.
    [21]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [22]
    VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400( 10360): 1345- 1362. DOI: 10.1016/S0140-6736(22)01200-4.
    [23]
    WEI Q, MU K, LI T, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression[J]. Lab Invest, 2014, 94( 1): 52- 62. DOI: 10.1038/labinvest.2013.126.
    [24]
    LIU BY, ZHOU ZW, JIN Y, et al. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma[J]. J Immunother Cancer, 2022, 10( 1): e003069. DOI: 10.1136/jitc-2021-003069.
    [25]
    THI HTH, HONG S. Inflammasome as a therapeutic target for cancer prevention and treatment[J]. J Cancer Prev, 2017, 22( 2): 62- 73. DOI: 10.15430/JCP.2017.22.2.62.
    [26]
    JIANG S, ZHANG Y, ZHENG JH, et al. Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation[J]. Pharmacol Res, 2017, 117: 82- 93. DOI: 10.1016/j.phrs.2016.11.040.
    [27]
    FAN SH, WANG YY, LU J, et al. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome[J]. PLoS One, 2014, 9( 2): e89961. DOI: 10.1371/journal.pone.0089961.
    [28]
    DALEY D, MANI VR, MOHAN N, et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma[J]. J Exp Med, 2017, 214( 6): 1711- 1724. DOI: 10.1084/jem.20161707.
    [29]
    DING Y, YAN YL, DONG YH, et al. NLRP3 promotes immune escape by regulating immune checkpoints: A pan-cancer analysis[J]. Int Immunopharmacol, 2022, 104: 108512. DOI: 10.1016/j.intimp.2021.108512.
    [30]
    WAN LF, YUAN X, LIU MT, et al. miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells[J]. Exp Ther Med, 2018, 15( 3): 2429- 2435. DOI: 10.3892/etm.2017.5667.
    [31]
    SONOHARA F, INOKAWA Y, KANDA M, et al. Association of inflammasome components in background liver with poor prognosis after curatively-resected hepatocellular carcinoma[J]. Anticancer Res, 2017, 37( 1): 293- 300. DOI: 10.21873/anticanres.11320.
    [32]
    WANG L, QIN XW, LIANG JM, et al. Induction of pyroptosis: A promising strategy for cancer treatment[J]. Front Oncol, 2021, 11: 635774. DOI: 10.3389/fonc.2021.635774.
    [33]
    CHEN YF, LI S, SHI Y, et al. Research progress on atherosclerosis induced by clonal hematopoiesis of indeterminate potential and the therapeutic effect of NLRP3 inflammasome[J]. China Med Herald, 2023, 20( 21): 40- 44. DOI: 10.20047/j.issn1673-7210.2023.21.08.

    陈雅芳, 李思, 史洋, 等. 潜质未定克隆性造血致动脉粥样硬化及NLRP3炎性小体治疗作用研究进展[J]. 中国医药导报, 2023, 20( 21): 40- 44. DOI: 10.20047/j.issn1673-7210.2023.21.08.
    [34]
    CHU Q, JIANG YN, ZHANG W, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma[J]. Oncotarget, 2016, 7( 51): 84658- 84665. DOI: 10.18632/oncotarget.12384.
    [35]
    CHEN YF, QI HY, WU FL. Euxanthone exhibits anti-proliferative and anti-invasive activities in hepatocellular carcinoma by inducing pyroptosis: Preliminary results[J]. Eur Rev Med Pharmacol Sci, 2018, 22( 23): 8186- 8196. DOI: 10.26355/eurrev_201812_16511.
    [36]
    WEI Q, ZHU R, ZHU JY, et al. E2-induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells[J]. Oncol Res, 2019, 27( 7): 827- 834. DOI: 10.3727/096504018X15462920753012.
    [37]
    SHARIF H, WANG L, WANG WL, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome[J]. Nature, 2019, 570( 7761): 338- 343. DOI: 10.1038/s41586-019-1295-z.
    [38]
    YAN ZL, DA QG, LI ZF, et al. Inhibition of NEK7 suppressed hepatocellular carcinoma progression by mediating cancer cell pyroptosis[J]. Front Oncol, 2022, 12: 812655. DOI: 10.3389/fonc.2022.812655.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (590) PDF downloads(46) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return